Summary
VCN Biosciences SL (VCN) is a biotechnology company that develops therapeutics for tumors. The company’s products VCN-01 are a tumor-selective replication-competent adenovirus expressing PH20 hyaluronidase, a glycosylphosphatidylinositol-anchored enzyme that degrades hyaluronan, and an important structural element of tumor extracellular matrix. It uses oncolytic adenovirus technology platform to design selective and efficient agents that replicate and self-amplify in tumor cells. VCN aims to develop agents for the treatment of cancer based on oncolytic adenoviruses with high potency and selectivity. The company develops new candidate viruses from its design, preclinical studies, and early efficacy studies in humans. VCN is headquartered in Sant Cugat del Valles, Spain.
VCN Biosciences SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
VCN Biosciences SL, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
VCN Biosciences Secures US$1.5 Million In First Round Of Financing 10
Licensing Agreements 12
VCN Biosciences Enters Into Licensing Agreement With IDIBELL 12
Acquisition 13
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 13
VCN Biosciences SL - Key Competitors 15
Key Employees 16
Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18
List of Tables
VCN Biosciences SL, Pharmaceuticals & Healthcare, Key Facts 1
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
VCN Biosciences SL, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
VCN Biosciences SL, Deals By Therapy Area, 2010 to YTD 2016 8
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
VCN Biosciences Secures US$1.5 Million In First Round Of Financing 10
VCN Biosciences Enters Into Licensing Agreement With IDIBELL 12
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 13
VCN Biosciences SL, Key Competitors 15
VCN Biosciences SL, Key Employees 16
List of Figures
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
VCN Biosciences SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8